{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rioci 1?<\/h3>\n

Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for pulmonal arteriel hypertension (PAH)<\/strong>. PAH er en specifik, progressiv og sj\u00e6lden sygdom \u2014 ikke det samme som systemisk hypertension<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n

What Is Rioci 1?<\/h2>\n

Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n

Pulmonal arteriel hypertension (PAH) er ikke systemisk hypertension.<\/strong> PAH refererer specifikt til forh\u00f8jet tryk i den pulmonale arterielle cirkulation (\u226520 mmHg gennemsnitligt pulmonalt arterieltryk med pulmonal vaskul\u00e6r resistens \u22652 Wood Units if\u00f8lge 2022 ESC\/ERS-retningslinjer). Det er sj\u00e6ldent (ansl\u00e5et 15-50 pr. million voksne), progressivt og uden behandling har det en d\u00e5rlig prognose (historisk 5-\u00e5rs overlevelse \u223c30%). Moderne PAH-m\u00e5lrettet behandling har forbedret 5-\u00e5rs overlevelsen til 60-70% p\u00e5 ekspertcentre.<\/p>\n

Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n

How Riociguat Works<\/h2>\n

Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n

Evidens<\/h2>\n

PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n

Dosering og monitorering<\/h2>\n

Dosering:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n

Overv\u00e5gning:<\/strong> ved baseline og derefter hver 3.-6. m\u00e5ned \u2014 WHO-funktionsklasse, 6-minutters gangdistance, NT-proBNP, gentaget ekkokardiografi og (med l\u00e6ngere intervaller) h\u00f8jrehjertekateterisering. Alt udf\u00f8rt gennem et specialiseret PAH-center.<\/p>\n

BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n

Bivirkninger<\/h2>\n